Aziz Kabeer, a director at AN2 Therapeutics, Inc., has disclosed a recent transaction involving 2,465 shares of the company's common stock. This transaction, filed on October 13, 2026, is part of Kabeer's ongoing engagement with the firm and highlights his significant ownership stake in the company.
As of the latest filing, Kabeer holds a total of 1,995,958 shares in AN2 Therapeutics. The transaction took place on October 12, 2026, and was reported under the SEC's Form 4, which is used to disclose changes in ownership by company insiders.
Background
AN2 Therapeutics, Inc. is a company focused on pharmaceutical preparations, classified under the SIC code 2834. The firm is incorporated in Delaware and operates out of Menlo Park, California. It trades under the ticker symbol ANTX and is listed on the appropriate exchanges. Kabeer's involvement as a director is significant in the context of the company's governance and strategic direction.
What the Filing Says
The SEC filing reveals that Kabeer acquired 2,465 shares, which were issued in lieu of cash compensation as part of the company's non-employee director compensation policy. All shares vested immediately, indicating a direct ownership change. Following this transaction, Kabeer owns 61,571 shares directly and has indirect ownership through two funds, holding 1,995,958 shares in total.
Impact
This transaction may affect various stakeholders, including investors, analysts, and other directors within AN2 Therapeutics. Kabeer's substantial ownership stake may influence decisions regarding the company's future direction and strategy, particularly in the competitive pharmaceutical landscape.
What's Next
The filing does not say what happens next.